PhRMA blasts Indian court's ruling against drug patent

The Pharmaceutical Research and Manufacturers of America rebuked India's Supreme Court for refusing to grant Novartis patent protection on its cancer medicine Glivec. The ruling is "another example of what I would characterize as a deteriorating innovation environment in India," said Chip Davis, PhRMA's executive vice president of advocacy. "[I]t is critically important that India promote a policy environment that supports continued research and development of new medicines for the health of patients in India and worldwide," PhRMA CEO John J. Castellani said.

View Full Article in:

Hill, The · New York Times (tiered subscription model), The · Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Actuary
Meridian Health Plan
Detroit, MI